Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration

α-Synuclein in Lewy bodies

Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382 · see citing works

Neurodegenerative diseases and oxidative stress

Barnham, K. J., Masters, C. L., & Bush, A. I. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1330 · Cited by 3,683 · see citing works

Oxidative Damage Linked to Neurodegeneration by Selective α-Synuclein Nitration in Synucleinopathy Lesions

Giasson, B. I., Duda, J. E., Murray, I. V. J., Chen, Q., Souza, J. M., Hurtig, H. I., Ischiropoulos, H., Trojanowski, J. Q., & Lee, V. M. ‐. (2000) · Science · doi:10.1126/science.290.5493.985 · Cited by 1,551 · see citing works

Metal-triggered Structural Transformations, Aggregation, and Fibrillation of Human α-Synuclein

Uversky, V. N., Li, J., & Fink, A. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105343200 · Cited by 1,103 · see citing works

Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease

McNaught, K. S. P., Perl, D. P., Brownell, A., & Olanow, C. W. (2004) · Annals of Neurology · doi:10.1002/ana.20186 · Cited by 548 · see citing works

Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice

LaVaute, T., Smith, S., Cooperman, S., Iwai, K., Land, W., Meyron-Holtz, E., Drake, S. K., Miller, G., Abu-Asab, M., Tsokos, M., et al. (2001) · Nature Genetics · doi:10.1038/84859 · Cited by 509 · see citing works

The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method.

Pakkenberg, B., Møller, A., Gundersen, H. J. G., Dam, A. M., & Pakkenberg, H. (1991) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.54.1.30 · Cited by 408 · see citing works

The Relevance of Iron in the Pathogenesis of Parkinson's Disease

Götz, M. E., Double, K. L., Gerlach, M., Youdim, M. B. H., & RIEDERERE, P. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1306.017 · Cited by 342 · see citing works

Proteasome inhibition causes nigral degeneration with inclusion bodies in rats

McNaught, K. S. P., rklund, L. M. B., Belizaire, R., Ole Isacson, A., Jenner, P. G., & Olanow, C. W. (2002) · Neuroreport · doi:10.1097/00001756-200208070-00018 · Cited by 275 · see citing works

Ubiquitin–proteasome system and Parkinson's diseases

Betarbet, R. S., Sherer, T., & Greenamyre, J. T. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.08.021 · Cited by 245 · see citing works

Regional Brain Iron, Ferritin and Transferrin Concentrations during Iron Deficiency and Iron Repletion in Developing Rats

Erikson, K. M., Piñero, D. J., Connor, J. R., & Beard, J. L. (1997) · Journal of Nutrition · doi:10.1093/jn/127.10.2030 · Cited by 237 · see citing works

Role of Cytochrome c as a Stimulator of α-Synuclein Aggregation in Lewy Body Disease

Hashimoto, M., Takeda, A., Hsu, L. J., Takenouchi, T., & Masliah, E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.41.28849 · Cited by 236 · see citing works

The Role of Iron in Neurodegeneration: Prospects for Pharmacotherapy of Parkinson??s Disease

Jellinger, K. A. (1999) · Drugs & Aging · doi:10.2165/00002512-199914020-00004 · Cited by 218 · see citing works

Iron and α-Synuclein in the Substantia Nigra of MPTP-Treated Mice: Effect of Neuroprotective Drugs R-Apomorphine and Green Tea Polyphenol (-)-Epigallocatechin-3-Gallate

Mandel, S. A., Maor, G., & Youdim, M. B. H. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:24:3:401 · Cited by 171 · see citing works

Update on Parkinson Disease

Siderowf, A. D., & Stern, M. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-8-200304150-00013 · Cited by 164 · see citing works

Recent developments in the pathology of Parkinson’s disease

Jellinger, K. A. (2002) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6139-5_33 · Cited by 154 · see citing works

Aggregation and neurotoxicity of α-synuclein and related peptides

EI-Agnaf, O. M. A., & Irvine, G. B. (2002) · Biochemical Society Transactions · doi:10.1042/bst0300559 · Cited by 151 · see citing works

Ca2+ Binding to α-Synuclein Regulates Ligand Binding and Oligomerization*

Nielsen, M., Vorum, H., Lindersson, E., & Jensen, P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101181200 · Cited by 150 · see citing works

Neurodegenerative disease and iron storage in the brain

Thomas, M., & Jankovic, J. J. (2004) · Current Opinion in Neurology · doi:10.1097/01.wco.0000137534.61244.d1 · Cited by 117 · see citing works

Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease

Faucheux, B. A., Martin, M., Beaumont, C., Hunot, S., Hauw, J., Agid, Y., & Hirsch, E. C. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01118.x · Cited by 116 · see citing works

Novel Chelators for Central Nervous System Disorders That Involve Alterations in the Metabolism of Iron and Other Metal Ions

Richardson, D. R. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1306.026 · Cited by 104 · see citing works

A clinical study on the relationship between the pineal gland and the opioid system

Lissoni, P., Esposti, D., Esposti, G., Mauri, R., Resentini, M., Morabito, F. C., Fumagalli, P., Santagostino, A., Delitala, G., & FRASCHINI, F. (1986) · Journal of Neural Transmission · doi:10.1007/bf01249612 · Cited by 91 · see citing works

Book Review: Iron and Parkinson’s Disease

Wolozin, B. L., & Golts, N. (2002) · The Neuroscientist · doi:10.1177/107385840200800107 · Cited by 89 · see citing works

Effect of advanced glycation endproducts on cell cycle and their relevance for Alzheimer’s disease

Münch, G. W., Gasic‐Milenkovic, J., & Arendt, T. (2003) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-0643-3_4 · Cited by 30 · see citing works

Oxidative stress and neurodegeneration: where are we now?

Halliwell, B. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03907.x · Cited by 2,614 · see citing works

Advances in the treatment of Parkinson's disease

Singh, N., Pillay, V., & Choonara, Y. E. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.11.009 · Cited by 396 · see citing works

Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples

Kell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361 · see citing works

Curcumin inhibits aggregation of α-synuclein

Pandey, N., Strider, J., Nolan, W. C., Yan, S. X., & Galvin, J. E. (2008) · Acta Neuropathologica · doi:10.1007/s00401-007-0332-4 · Cited by 265 · see citing works

Single Particle Characterization of Iron-induced Pore-forming α-Synuclein Oligomers

Kostka, M., Högen, T., Danzer, K. M., Levin, J., Habeck, M., Wirth, A., Wagner, R., Glabe, C. G., Finger, S., Heinzelmann, U., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709634200 · Cited by 230 · see citing works

Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement

Pan, T., Kondo, S., Zhu, W., Xie, W., Jankovic, J. J., & Le, W. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.06.003 · Cited by 210 · see citing works

Iron metabolism in Parkinsonian syndromes

Berg, D., & Hochstrasser, H. (2006) · Movement Disorders · doi:10.1002/mds.21020 · Cited by 185 · see citing works

Brain Iron Metabolism Dysfunction in Parkinson’s Disease

Jiang, H. F., Wang, J., Rogers, J. T., & Xie, J. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9879-1 · Cited by 183 · see citing works

SPY1 inhibits neuronal ferroptosis in amyotrophic lateral sclerosis by reducing lipid peroxidation through regulation of GCH1 and TFR1

Wang, D., Liang, W., Huo, D., Wang, H., Wang, Y., Cong, C., Zhang, C., Yan, S., Gao, M., Su, X., et al. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-01089-7 · Cited by 157 · see citing works

Oxidative Stress in Parkinson’s Disease: Potential Benefits of Antioxidant Supplementation

Percário, S., Barbosa, A. D. S., Varela, E. L. P., Gomes, A. R. Q., Ferreira, M. E. S., Moreira, T. D. N. A., & Dolabela, M. F. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/2360872 · Cited by 154 · see citing works

Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease

Vernon, A. C., Johansson, S., & Modo, M. (2010) · BMC Neuroscience · doi:10.1186/1471-2202-11-1 · Cited by 147 · see citing works

Prevention and restoration of lactacystin‐induced nigrostriatal dopamine neuron degeneration by novel brain‐permeable iron chelators

Zhu, W., Xie, W., Pan, T., Xu, P., Fridkin, M., Zheng, H., Jankovic, J. J., Youdim, M. B. H., & Le, W. (2007) · The FASEB Journal · doi:10.1096/fj.07-8386com · Cited by 137 · see citing works

Neuroprotection by Spirulina platensis protean extract and phycocyanin against iron-induced toxicity in SH-SY5Y neuroblastoma cells

Bermejo-Bescós, P., Piñero-Estrada, E., & Villar del Fresno, Á. M. (2008) · Toxicology in Vitro · doi:10.1016/j.tiv.2008.05.004 · Cited by 134 · see citing works

Neuroprotective effect of the natural iron chelator, phytic acid in a cell culture model of Parkinson's disease

Xu, Q., Kanthasamy, A. G., & Reddy, M. B. (2007) · Toxicology · doi:10.1016/j.tox.2007.12.017 · Cited by 121 · see citing works

Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1α and induction of autophagy in SH-SY5Y cells

Wu, Y., Li, X., Xie, W., Jankovic, J. J., Le, W., & Pan, T. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.05.008 · Cited by 115 · see citing works

Phytic Acid Protects against 6-Hydroxydopamine-Induced Dopaminergic Neuron Apoptosis in Normal and Iron Excess Conditions in a Cell Culture Model

Xu, Q., Kanthasamy, A. G., & Reddy, M. B. (2011) · Parkinson s Disease · doi:10.4061/2011/431068 · Cited by 112 · see citing works

Ferroportin 1 but not hephaestin contributes to iron accumulation in a cell model of Parkinson's disease

Song, N., Wang, J., Jiang, H. F., & Xie, J. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.11.004 · Cited by 109 · see citing works

Proteasome inhibition modeling nigral neuron degeneration in Parkinson’s disease

Xie, W., Li, X., Li, C., Zhu, W., Jankovic, J. J., & Le, W. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06914.x · Cited by 105 · see citing works

Oxidative stress in neurodegeneration and available means of protection

Fatokun, A. A. (2008) · Frontiers in bioscience · doi:10.2741/2926 · Cited by 105 · see citing works

Δ9‐tetrahydrocannabinol (Δ9‐THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease

Carroll, C., Zeissler, M., Hanemann, C. O., & Zajicek, J. (2012) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2011.01248.x · Cited by 104 · see citing works

Coenzyme Q10 Provides Neuroprotection in Iron-Induced Apoptosis in Dopaminergic Neurons

Kooncumchoo, P., SHARMA, S. K., Porter, J. E., Govitrapong, P., & Ebadi, M. (2006) · Journal of Molecular Neuroscience · doi:10.1385/jmn:28:2:125 · Cited by 100 · see citing works

Genetics of iron regulation and the possible role of iron in Parkinson's disease

Rhodes, S. L., & Ritz, B. R. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.07.001 · Cited by 99 · see citing works

Beneficial Effects of Spirulina Consumption on Brain Health

Trotta, T., Porro, C., Cianciulli, A., & Panaro, M. A. (2022) · Nutrients · doi:10.3390/nu14030676 · Cited by 98 · see citing works

Prevention of Motor Neuron Degeneration by Novel Iron Chelators in SOD1G93A Transgenic Mice of Amyotrophic Lateral Sclerosis

Wang, Q., Zhang, X., Chen, S., Zhang, X., Zhang, S., Youdium, M. B. H., & Le, W. (2011) · Neurodegenerative Diseases · doi:10.1159/000323469 · Cited by 93 · see citing works

Pooled analysis of iron-related genes in Parkinson's disease: Association with transferrin

Rhodes, S. L., Buchanan, D. D., Ahmed, I., Taylor, K. D., Loriot, M., Sinsheimer, J. S., Bronstein, J. M., Elbaz, A., Mellick, G. D., Rotter, J. I., et al. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.09.019 · Cited by 87 · see citing works

Genetic findings in Parkinson’s disease and translation into treatment: a leading role for mitochondria?

Bogaerts, V., Theuns, J., & Broeckhoven, C. V. (2007) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2007.00342.x · Cited by 86 · see citing works

Metallobiology of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity

Hare, D. J., Adlard, P. A., Doble, P. A., & Finkelstein, D. I. (2013) · Metallomics · doi:10.1039/c2mt20164j · Cited by 78 · see citing works

Chelators in the Treatment of Iron Accumulation in Parkinson's Disease

Mounsey, R. B., & Teismann, P. (2012) · International Journal of Cell Biology · doi:10.1155/2012/983245 · Cited by 81 · see citing works

Targeting the Progression of Parkinsons Disease

George, J., Mok, S., Moses, D., Wilkins, S., Bush, A., Cherny, R., & Finkelstein, D. (2009) · Current Neuropharmacology · doi:10.2174/157015909787602814 · Cited by 77 · see citing works

Iron chelation and neuroprotection in neurodegenerative diseases

Li, X., Jankovic, J. J., & Le, W. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0518-0 · Cited by 75 · see citing works

Iron Chelation Nanoparticles with Delayed Saturation as an Effective Therapy for Parkinson Disease

Wang, N., Jin, X., Guo, D., Tong, G., & Zhu, X. (2016) · Biomacromolecules · doi:10.1021/acs.biomac.6b01547 · Cited by 71 · see citing works

Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and Its Analogues as Highly Potent Dopamine D2/D3 Agonists and as Iron Chelator: In Vivo Activity Indicates Potential Application in Symptomatic and Neuroprotective Therapy for Parkinson’s Disease

Ghosh, B., Antonio, T., Reith, M. E. A., & Dutta, A. K. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901618d · Cited by 70 · see citing works

Environmental neurotoxic chemicals-induced ubiquitin proteasome system dysfunction in the pathogenesis and progression of Parkinson's disease

SUN, F., KANTHASAMY, A. G., ANANTHARAM, V., & KANTHASAMY, A. G. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.04.001 · Cited by 69 · see citing works

Adaptive changes in autophagy after UPS impairment in Parkinson's disease

Shen, Y.-F., Tang, Y., Zhang, X.-J., Huang, K.-X., & Le, W.-D. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2012.203 · Cited by 62 · see citing works

Subchronic Polychlorinated Biphenyl (Aroclor 1254) Exposure Produces Oxidative Damage and Neuronal Death of Ventral Midbrain Dopaminergic Systems

Lee, D. W., Notter, S. A., Thiruchelvam, M. J., Dever, D. P., Fitzpatrick, R., Kostyniak, P. J., Cory‐Slechta, D. A., & Opanashuk, L. A. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfr313 · Cited by 63 · see citing works

Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin‐induced nigrostriatal dopaminergic degeneration

Zhu, W., Xie, W., Pan, T., Jankovic, J. J., Li, J., Youdim, M. B. H., & Le, W. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05330.x · Cited by 59 · see citing works

Alpha-synuclein, Proteotoxicity and Parkinson's Disease: Search for Neuroprotective Therapy

Ganguly, U., Chakrabarti, S. S., Kaur, U., Mukherjee, A., & Chakrabarti, S. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666171129100944 · Cited by 56 · see citing works

The lipophilic metal chelators DP‐109 and DP‐460 are neuroprotective in a transgenic mouse model of amyotrophic lateral sclerosis

Petri, S., Calingasan, N. Y., Alsaied, O. A., Wille, E., Kiaei, M., Friedman, J. E., Baranova, O., Chavez, J. C., & Beal, M. F. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04604.x · Cited by 55 · see citing works

Reversion of age-related recognition memory impairment by iron chelation in rats

de Lima, M. N. M., Dias, C. P., Torres, J. P., Dornelles, A. D. S., Garcia, V. A., Scalco, F. S., Guimarães, M. R., Petry, R. C., Bromberg, E., Constantino, L. D. S., et al. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.006 · Cited by 55 · see citing works

Genetics and iron in the systems biology of Parkinson’s disease and some related disorders

Funke, C., Schneider, S. A., Berg, D., & Kell, D. B. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.11.015 · Cited by 54 · see citing works

Genetic iron chelation protects against proteasome inhibition-induced dopamine neuron degeneration

Zhu, W., Li, X., Xie, W., Luo, F., Kaur, D., Andersen, J. K., Jankovic, J. J., & Le, W. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.09.024 · Cited by 53 · see citing works

Role of α-synuclein aggregation and the nuclear factor E2-related factor 2/heme oxygenase-1 pathway in iron-induced neurotoxicity

He, Q. W., Song, N., Jia, F., Xu, H., Yu, X., Xie, J., & Jiang, H. F. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.02.012 · Cited by 52 · see citing works

Metal specificity of an iron-responsive element in Alzheimer’s APP mRNA 5′untranslated region, tolerance of SH-SY5Y and H4 neural cells to desferrioxamine, clioquinol, VK-28, and a piperazine chelator

Bandyopadhyay, S., Huang, X., Cho, H. K., Greig, N. H., Youdim, M. B. H., & Rogers, J. T. (2006) · Springer eBooks · doi:10.1007/978-3-211-33328-0_25 · Cited by 51 · see citing works

Neuroprotection of Pramipexole in UPS Impairment Induced Animal Model of Parkinson’s Disease

Li, C., Guo, Y. L., Xie, W., Li, X., Janokovic, J., & Le, W. (2010) · Neurochemical Research · doi:10.1007/s11064-010-0214-3 · Cited by 49 · see citing works

Evolution of Extra-Nigral Damage Predicts Behavioural Deficits in a Rat Proteasome Inhibitor Model of Parkinson's Disease

Vernon, A. C., Crum, W. R., Johansson, S., & Modo, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017269 · Cited by 46 · see citing works

Multiple Molecular Pathways Are Involved in the Neuroprotection of GDNF Against Proteasome Inhibitor Induced Dopamine Neuron Degeneration In Vivo

Du, Y., Li, X., Yang, D., Zhang, X., Chen, S., Huang, K., & Le, W. (2008) · Experimental Biology and Medicine · doi:10.3181/0712-rm-329 · Cited by 41 · see citing works

Role of iron in UPS impairment model of Parkinson's disease

Le, W. (2013) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(13)70038-5 · Cited by 36 · see citing works

Nurr1 deficiency predisposes to lactacystin-induced dopaminergic neuron injury in vitro and in vivo

Pan, T., Zhu, W., Zhao, H., Deng, H., Xie, W., Jankovic, J. J., & Le, W. (2008) · Brain Research · doi:10.1016/j.brainres.2008.05.022 · Cited by 35 · see citing works

Changes in iron-regulatory gene expression occur in human cell culture models of Parkinson’s disease

Carroll, C., Zeissler, M., Chadborn, N., Gibson, K., Williams, G. T., Zajicek, J., Morrison, K. E., & Hanemann, C. O. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.05.006 · Cited by 34 · see citing works

Anti-Parkinsonian Effects of Nurr1 Activator in Ubiquitin-Proteasome System Impairment Induced Animal Model of Parkinson’s Disease

Zhang, Z., Li, X., Xie, W., Tuo, H., Hintermann, S., Jankovic, J. J., & Le, W. (2012) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152712803581155 · Cited by 32 · see citing works

Asymmetric Electrophilic α-Amination of Silyl Enol Ether Derivatives via the Nitrosocarbonyl Hetero-ene Reaction

Sandoval, D., Samoshin, A. V., & de Alaniz, J. R. (2015) · Organic Letters · doi:10.1021/acs.orglett.5b02208 · Cited by 31 · see citing works

Therapeutic potential of iron chelators in diseases associated with iron mismanagement

Weinberg, E. D. (2006) · The Journal of pharmacy and pharmacology · doi:10.1211/jpp.58.5.0001 · Cited by 29 · see citing works

The Relevancy of Data Regarding the Metabolism of Iron to Our Understanding of Deregulated Mechanisms in ALS; Hypotheses and Pitfalls

Petillon, C., Hergesheimer, R. C., Puy, H., Corcia, P., Vourc’h, P., Andres, C. R., Karim, Z., & Blasco, H. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.01031 · Cited by 28 · see citing works

Iron overload resulting from the chronic oral administration of ferric citrate induces parkinsonism phenotypes in middle-aged mice

Huang, C., Ma, W., Luo, Q., Shi, L., Xia, Y., Lao, C., Liu, W., Zou, Y., Cheng, A., Shi, R., et al. (2019) · Aging · doi:10.18632/aging.102433 · Cited by 27 · see citing works

Deletion of Herp facilitates degradation of cytosolic proteins

Miura, H., Hashida, K., Sudo, H., Awa, Y., Takarada‐Iemata, M., Kokame, K., Takahashi, T., Matsumoto, M., Kitao, Y., & Hori, O. (2010) · Genes to Cells · doi:10.1111/j.1365-2443.2010.01422.x · Cited by 25 · see citing works

Proteomic Analysis of Testis Biopsies in Men Treated with Injectable Testosterone Undecanoate Alone or in Combination with Oral Levonorgestrel as Potential Male Contraceptive

Cui, Y., Zhu, H., Zhu, Y., Guo, X., Huo, R., Wang, X., Tong, J.-S., Qian, L.-X., Zhou, Z., Jia, Y., et al. (2008) · Journal of Proteome Research · doi:10.1021/pr800259t · Cited by 26 · see citing works

Glial Cell-Derived Neurotrophic Factor Protects Against Proteasome Inhibition-Induced Dopamine Neuron Degeneration by Suppression of Endoplasmic Reticulum Stress and Caspase-3 Activation

Li, X., Peng, C., Li, L., Ming, M., Yang, D., & Le, W. (2007) · The Journals of Gerontology Series A · doi:10.1093/gerona/62.9.943 · Cited by 26 · see citing works

Proteasome inhibitor lactacystin disturbs the intracellular calcium homeostasis of dopamine neurons in ventral mesencephalic cultures

LI, X., Yang, D., Li, T., Peng, C., Chen, S., & Le, W. D. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.04.014 · Cited by 24 · see citing works

c-Jun N-Terminal Kinase Mediates Lactacystin-Induced Dopamine Neuron Degeneration

Li, X., Du, Y., Fan, X., Yang, D., Luo, G., & Le, W. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318186de64 · Cited by 24 · see citing works

Optically Pure N-Hydroxy-O-triisopropylsilyl-α- l -amino Acid Methyl Esters from AlCl3-Assisted Ring Opening of Chiral Oxaziridines by Nitrogen Containing Nucleophiles

Gioia, M. L. D., Leggio, A., Pera, A. L., Liguori, A., & Siciliano, C. (2005) · The Journal of Organic Chemistry · doi:10.1021/jo051890+ · Cited by 23 · see citing works

The effects of n-acetylcysteine and/or deferoxamine on manic-like behavior and brain oxidative damage in mice submitted to the paradoxal sleep deprivation model of mania

Arent, C. O., Valvassori, S. S., Steckert, A. V., Resende, W. R., Dal-Pont, G. C., Lopes-Borges, J., Amboni, R. T., Bianchini, G., & Quevedo, J. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.04.011 · Cited by 21 · see citing works

Molecular pathways and genetic aspects of Parkinson’s disease: from bench to bedside

Napoli, M. D., Shah, I. M., & Stewart, D. A. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.12.1693 · Cited by 19 · see citing works

Isolation of Salsolinol, a Tetrahydroisoquinoline Alkaloid, from the Marine Sponge Xestospongia cf. vansoesti as a Proteasome Inhibitor

Nagasawa, Y., Ueoka, R., Yamanokuchi, R., Horiuchi, N., Ikeda, T., Rotinsulu, H., Mangindaan, R. E. P., Ukai, K., Kobayashi, H., Namikoshi, M., et al. (2011) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.59.287 · Cited by 19 · see citing works

Neuroprotection of desferrioxamine in lipopolysaccharide-induced nigrostriatal dopamine neuron degeneration

Zhang, K. (2011) · Molecular Medicine Reports · doi:10.3892/mmr.2011.671 · Cited by 19 · see citing works

Literature-Related Discovery (LRD)

Kostoff, R. N., Block, J. A., Solka, J. L., Briggs, M. B., Rushenberg, R. L., Stump, J. A., Johnson, D., Lyons, T. J., & Wyatt, J. R. (2007) · Defense Technical Information Center (DTIC) · doi:10.21236/ada473438 · Cited by 19 · see citing works

Inhibition of vascular adhesion protein 1 protects dopamine neurons from the effects of acute inflammation and restores habit learning in the striatum

Becchi, S., Buson, A., & Balleine, B. W. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02288-8 · Cited by 18 · see citing works

ATH434 Rescues Pre-motor Hyposmia in a Mouse Model of Parkinsonism

Beauchamp, L. C., Liu, X. M., Vella, L. J., Adlard, P. A., Bush, A. I., Finkelstein, D. I., & Barnham, K. J. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01300-0 · Cited by 15 · see citing works

Dietary chelators as antioxidant enzyme mimetics: implications for dietary intervention in neurodegenerative diseases

Hague, T., Andrews, P. L. R., Barker, J., & Naughton, D. P. (2006) · Behavioural Pharmacology · doi:10.1097/00008877-200609000-00008 · Cited by 12 · see citing works

Trifluoromethyl nitrones: from fluoral to optically active hydroxylamines

Milcent, T., Hinks, N., Bonnet‐Delpon, D., & Crousse, B. (2010) · Organic & Biomolecular Chemistry · doi:10.1039/c001791d · Cited by 13 · see citing works

Deferiprone Protects against Photoreceptor Degeneration Induced by Tunicamycin in the Rat Retina

Shirai, Y., Mori, A., Nakahara, T., Sakamoto, K., & Ishii, K. (2015) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b15-00185 · Cited by 13 · see citing works

Novel 1-hydroxypyridin-2-one metal chelators prevent and rescue ubiquitin proteasomal-related neuronal injury in an in vitro model of Parkinson’s disease

Lewis, F. W., Fairooz, S., Elson, J. L., Hubscher‐Bruder, V., Brandel, J., Soundararajan, M., Smith, D. P., Dexter, D. T., Tétard, D., & Pienaar, I. S. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02672-y · Cited by 13 · see citing works

Drug Targets from Genetics: Alpha-Synuclein

Danzer, K. M., & McLean, P. J. (2011) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152711797247867 · Cited by 13 · see citing works

Dequalinium-Induced Cell Death of Yeast Expressing α-Synuclein-GFP Fusion Protein

Lee, I., Kim, H.-Y., Kim, M., Hahn, J., & Paik, S. R. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9598-8 · Cited by 11 · see citing works

The Role and Mechanisms of Ubiquitin-Proteasome System-Mediated Ferroptosis in Neurological Disorders

Liu, X., Wang, W., Nie, Q., Liu, X., Sun, L., Ma, Q., Zhang, J., & Wei, Y. (2025) · Neuroscience Bulletin · doi:10.1007/s12264-024-01343-7 · Cited by 6 · see citing works

Fibroblast growth factor-21 alleviates proteasome injury via activation of autophagy flux in Parkinson’s disease

Shen, Y., Zhu, Z., Wang, Y., Qian, S., Xu, C., & Zhang, B. (2023) · Experimental Brain Research · doi:10.1007/s00221-023-06709-3 · Cited by 4 · see citing works

Pharmacological strategies for Parkinson’s disease

García-Montes, J.-R., Boronat-García, A., & Drucker-Colı́n, R. (2012) · Health · doi:10.4236/health.2012.431174 · Cited by 3 · see citing works

Current Concepts on the Etiology and Pathogenesis of Parkinson Disease

Fahn, S., Jankovic, J. J., Hallett, M., & Jenner, P. G. (2007) · Elsevier eBooks · doi:10.1016/b978-0-443-07941-2.50008-5 · Cited by 1 · see citing works

Papel do sistema ubiquitina-proteassoma na formação da memória e suas alterações em um modelo de disfunção cognitiva associada ao acúmulo cerebral de ferro

Figueiredo, L. S. (2015) · Americanae (AECID Library)

Proteomics of mouse cortex following conditional deletion of Psmc1 proteasomal subunit in neurones

Elkharaz, J. (2013) · Nottingham ePrints (University of Nottingham)

MRI assessment of brain iron content in methamphetamine users

Berlow, Y. A. (2014) · doi:10.6083/m4028q7c

The Effects of Prolyl Oligopeptidase Inhibition in α-Synuclein Based Mouse Models of Parkinson's Disease

Savolainen, M. H. (2015) · Työväentutkimus Vuosikirja

Structural andT hermodynamic Studies of a-Synuclein Proteins Related to Parkinson’s Disease

(2011) · CRC Press eBooks · doi:10.1201/b10835-3

GDNF and Neurturin isoforms in an experimental model of Parkinson's disease

Penttinen, A. (2017) · Työväentutkimus Vuosikirja

The Critical Roleplay of Iron Neurochemistry in Progression of Parkinson’s Disease

Sharma, G., Kadian, M., Sharma, K., Pandita, S., Shrivasatava, K., & Kumar, A. (2022) · Nutritional neurosciences · doi:10.1007/978-981-19-7327-7_5

Additional file 1 of Inhibition of vascular adhesion protein 1 protects dopamine neurons from the effects of acute inflammation and restores habit learning in the striatum

Becchi, S., Buson, A., & Balleine, B. W. (2021) · Figshare · doi:10.6084/m9.figshare.16821686

Role of endolysosome iron in amyloid-β protein-induced increases in reactive oxygen species, mitochondrial depolarization, and cytotoxicity

Quansah, D., Halcrow, P., Kumar, N., Liang, B., & Geiger, J. D. (2026) · Journal of Alzheimer's Disease · doi:10.1177/13872877261449714

BindingDB Entry 50031129: Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkin

BindingDB (2010) · UC San Diego · doi:10.7270/q20k28qz

Neuroprotective effect of phytic acid in Parkinson's disease

Xu, Q. (2007) · doi:10.31274/rtd-180813-15813

Genetic iron chelation protects against proteasome inhibition-induced dopamine neuron degeneration

Zhu, W., Li, X., Xie, W., Luo, F., Kaur, D., Andersen, J. K., Jankovic, J. J., & Le, W. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.09.024 · Cited by 53 · see citing works

Role of iron in UPS impairment model of Parkinson's disease

Le, W. (2013) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(13)70038-5 · Cited by 36 · see citing works

Prevention and restoration of lactacystin‐induced nigrostriatal dopamine neuron degeneration by novel brain‐permeable iron chelators

Zhu, W., Xie, W., Pan, T., Xu, P., Fridkin, M., Zheng, H., Jankovic, J. J., Youdim, M. B. H., & Le, W. (2007) · The FASEB Journal · doi:10.1096/fj.07-8386com · Cited by 137 · see citing works

Novel 1-hydroxypyridin-2-one metal chelators prevent and rescue ubiquitin proteasomal-related neuronal injury in an in vitro model of Parkinson’s disease

Lewis, F. W., Fairooz, S., Elson, J. L., Hubscher‐Bruder, V., Brandel, J., Soundararajan, M., Smith, D. P., Dexter, D. T., Tétard, D., & Pienaar, I. S. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02672-y · Cited by 13 · see citing works

A Mechanistic Study of Proteasome Inhibition-Induced Iron Misregulation in Dopamine Neuron Degeneration

Li, X., Xie, W., Zhang, Z., Kansara, S., Jankovic, J. J., & Le, W. (2012) · Neurosignals · doi:10.1159/000332954 · Cited by 26 · see citing works